OPEN END-TURBO-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - BOERSE MUENCHEN 20:35:07 28/06/2024 BST | ||
| 16.36 EUR | -1.45% |
|
| 1 month | +16.44% | ||
| 3 months | +37.36% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 16.36 | -1.45% |
| 27/06/24 | 16.6 | +0.18% |
| 26/06/24 | 16.57 | +0.91% |
| 25/06/24 | 16.42 | -1.50% |
| 24/06/24 | 16.67 | +2.77% |
Real-time BOERSE MUENCHEN
Last update June 28, 2024 at 08:35 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | HSBC |
| WKN | HG46UL |
| ISIN | DE000HG46UL5 |
| Date issued | 07/07/2022 |
| Strike | 298.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.78 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 17.59 € |
|---|---|
| Lowest since issue | 2.02 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Certificates
- Certificat
